Charles Schwab
RCPI

Charles Schwab’s ROCK CREEK PHARMACEUTICALS INC COM STK (DE) RCPI Stock Holding History

Charles Schwab’s Portfolio RCPI Stock Details RCPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4,765
Closed -$71K – 3091
2014
Q2 		$71K Buy
+4,765
New +$82.7K ﹤0.01% 3068

Other funds holding RCPI

GCM
Goldman Capital Management New York $103M AUM 21.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TC
Talkot Capital Sausalito, California $73.7M AUM 8.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Kempner Capital Management Galveston, Texas $106M AUM 29.1% 1-Year Est. Return

Charles Schwab's RCPI Position: Q3 2014 in Review

Charles Schwab sold out of ROCK CREEK PHARMACEUTICALS INC COM STK (DE) (RCPI) in Q3 2014, closing a stake of 4,765 shares — an estimated $71K sold.

Charles Schwab first reported a position in RCPI in Q2 2014 and held it in 1 quarter. The position peaked at $71K in Q2 2014. 67 funds tracked by Wall St. Rank hold RCPI as of Q3 2014.

  • Charles Schwab reported no remaining ROCK CREEK PHARMACEUTICALS INC COM STK (DE) position as of Q3 2014 after selling out during the quarter.
  • Charles Schwab sold 4,765 ROCK CREEK PHARMACEUTICALS INC COM STK (DE) shares in Q3 2014, an estimated $71K.
  • Charles Schwab first reported a position in ROCK CREEK PHARMACEUTICALS INC COM STK (DE) in Q2 2014 and held it in 1 quarter.
  • Charles Schwab's ROCK CREEK PHARMACEUTICALS INC COM STK (DE) position peaked at $71K in Q2 2014.
  • 67 funds tracked by Wall St. Rank held ROCK CREEK PHARMACEUTICALS INC COM STK (DE) as of Q3 2014.

Based on Charles Schwab's 13F filing for Q3 2014, filed 10 Nov 2014.